Thought #3:

Other thought: Operating Loss for Elite has been been between 431k and 607k in the last four quarters. last quarter operating loss was 515k. So really Elite needs to increase revenue another $2,000,000/year to break even. Given that total revenue last quarter ending 9/30 was $635,000 that's a pace of $2,500,000/year. So they need to reach $4,500,000 a year in revenue to achieve break-even.

The estimated annual revenue of currently launched products in my (hopefully) reasonably accurate spreadsheet is $5,900,000. (I took out the two new Phentermine products til they actually ship).

So whats the point of all of this rambling? If Elite doesn't launch another single product they should, within a year, be operationally cash flow positive to the tune of about $1,400,000 per year. That means they could pay off their total debt in about 3 to 3.5 years.

If they announce Naltrexone and the Phentermine products within the next two months then we are approaching $8,000,000/year annually. That would mean they could pay off debt in about 2 years.

So, even without ART products (the "Home Run") you could own stock in a DEBT FREE, Cash-Flow- Positive stock that generates $4,000,000/year in positive cash flow/net income.